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Saroglitazar is a dual PPAR a/g agonist approved in India for the management of diabetic
dyslipidemia.
Aims: The objective of this study was to evaluate the safety and efficacy of saroglitazar 4 mg
once daily in clinical practice.
Methods: This was an observational, multicenter, single-arm study. Patients with type 2
diabetes (with on-going antidiabetic medication), age above 18 years, and triglycerides
200 mg/dL were included.
Results: A total 2804 patients with a mean duration of diabetes 6.29 yrs were included in this
analysis. The baseline demographic profile was: mean age of 53 yrs, mean body weight
72.3 kg and mean BMI of 27 kg/m2. 62.5% patients were male and 57.8% were reported to be
on statin therapy at baseline. All 2804 patients were on antidiabetic medications with 15.4%
patients on monotherapy and rest were on two or more than two antidiabetic medications
at baseline. The baseline triglycerides and HbA1C values were 312.3 mg/dL and 8.3%
respectively. At 3 months follow-up, use of saroglitazar 4 mg led to significant reduction in
TG (35.8%), LDL-C (16.4%), total cholesterol (19%) and non-HDL-C (23.4%). Addition of sar-
oglitazar to baseline antidiabetic medications showed a significant 0.9% absolute reduction
in HbA1c with significant improvement in fasting and post prandial plasma glucose. No
serious adverse events, alteration in liver or renal enzymes and edema or weight gain were
reported.
Conclusion: Saroglitazar is a potential therapeutic option in type 2 diabetic patients with
high TG levels, not controlled by statins, for comprehensive control of lipid and glycemic
parameters with acceptable safety profile.
Copyright © 2015, Cardiological Society of India. All rights reserved.dila.com (A.D. Jaiswal).
ociety of India. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 2 3e2 6241. IntroductionThe cardiovascular diseases (CVDs) burden globally and aswell
in India is rising sharply and presently is the number one cause
of mortality.1 INTERHEART study, a major Canadian-led global
study identified 9 easily measured risk factors (smoking, lipids,
hypertension, diabetes, obesity, diet, physical activity, alcohol
consumption, and psychosocial factors) that account for over
90% of the risk of acute myocardial infarction (AMI) and dysli-
pidemia being the strongest risk predictor globally.2 Diabetic
dyslipidemia (DD) is an important factor contributing to the
increased risk of CVDs.3 Studies have shown that three out of
four diabetes patients globally have associated dyslipidemia.4
DD, also known as atherogenic dyslipidemia, is the triad of
high triglycerides (TG), higher proportion of small dense low
density lipoprotein cholesterol (sd-LDL-C) and low high density
lipoprotein cholesterol (HDL-C).5 Currently statins, fibrates,
niacin and omega 3 fatty acids are the available drugs in the
armamentarium for the treatment of dyslipidemia. Saroglitazar
is the novel molecule approved in India for themanagement of
DD. It is thefirst dual peroxisomeproliferator activated receptor
(PPAR)-a/g agonist to have successfully completed its clinical
research and to be approved for clinical use anywhere in the
world. In previous studies, saroglitazar has shown significant
benefit in terms of improvement in lipid and glycemic param-
eters with good safety profile. There has been a 46.7% decrease
in TG, 32.5% decrease in non-HDL-C, 0.3% absolute reduction in
glycosylated hemoglobin (HbA1c) with saroglitazar 4 mg in In-
dian DD patients.6,7 The present observational study was done
to evaluate the safety and efficacy of saroglitazar in Indian DD
patients in clinical practice.Table 1 e Demographic profile of patients (N ¼ 3133).
Age (years); n ¼ 3100 53 ± 10
Male 1958 (62.5%)
Weight (kg); n ¼ 2737 72.3 ± 11.45
BMI (kg/m2); n ¼ 2565 27.0 ± 4.17
Average duration of diabetes (years); n ¼ 2562 6.29 ± 6.20
Data are mean ± SD values or number (%) as indicated. Abbrevia-
tions: N¼ number of subjects in specified treatment; n¼ number of
subjects at specified category; BMI ¼ body mass index. Data
Determined at baseline.2. Methodology
This was an observational, multicenter, single-arm, post
marketing study of saroglitazar 4 mg in Indian DD patients (at
outpatient clinic settings) who were prescribed saroglitazar
4 mg once daily as per the approved indication (diabetic dys-
lipidemia and hypertriglyceridemia in type 2 diabetes not
controlled with statin). Only patients who qualified for sar-
oglitazar treatment as per treating physician's clinical judg-
ment (as per prescribing information of saroglitazar) in out-
patient settings were included in this analysis. There was no
experimental intervention done. Patients with type 2 diabetes
(with on-going antidiabetic medication), age above 18 years
and triglycerides 200 mg/dL were included. The exclusion
criteria were pregnancy, lactating mothers, active liver dis-
ease, NYHA class III or IV heart failure,malignancy, or patients
with history of hypersensitivity to saroglitazar or any of the
excipients used in the formulation. The data were collected
from the treating physicians who had prescribed saroglitazar
between November 2013 and July 2014. In this observational
analysis, 3133 patient data were obtained and only those with
antidiabeticmedications recordedat baselinewere included in
the final analysis. Antidiabetic medications at baseline were
not reported in 329 patients, hence 2804 patient data were
considered. All these 2804 patients were prescribed tablet
saroglitazar 4 mg once daily before breakfast. Baseline and3month glycemic parameters (HbA1c, Fasting plasma glucose,
post-prandial plasma glucose), lipid parameters (total choles-
terol, LDL-C, HDL-C, TG, non-HDL-C) and adverse event if any
reported were recorded. The laboratory tests were conducted
at centers recommended by treating physicians. The LDL-C
values are direct, not calculated from Friedewald equation.
Non-HDL-C was calculated by subtracting HDL-C value from
total cholesterol value. Only those patient datawhichhadboth
baseline and 3 month follow up data were considered for in-
dividual laboratory parameters analysis (e.g. in Table 4, for the
analysis of effect on TG, out of the total 2804 patient data, 2767
were used for analysis as they had both baseline and 3 month
follow up TG values recorded). The SAS® system for Windows
(release 9.3; SAS Institute) was used for statistical analysis.
Significant differences in the means from baseline to post
baselinewere assessed by paired t-tests. “p” value of <0.05was
considered as significant.3. Results
The data of 3133 patients prescribed saroglitazar 4 mg once
daily was recorded at baseline and at 3 months and analyzed.
All were type 2 diabetes patients with average duration of
diabetes of 6.29 years. The mean age of the patients was 53
years and 62.5% of the patients were male. The patients had a
mean weight of 72.3 kgs and a mean body mass index of
27.0 kg/m2 (Table 1). Out of 3133 patients, 284 were reported to
have history of coronary heart disease.
In this study 57.8% of patients were reported to be on statin
therapy, with atorvastatin being the most commonly used
statin (69.6%), at the time of entry (Table 2). All patients were
advised to continue on-going statin therapy and saroglitazar
4 mg once daily was prescribed as 2nd line lipid-lowering
agent.
Out of 3133 patients, concomitant antidiabeticmedications
at baseline were recorded in 2804 patients (89.5%) and only
these patient data were utilized for further analysis. Sar-
oglitazar 4 mg was prescribed in addition to on-going single
antidiabetic therapy in 15.4%, to on-going dual antidiabetic
therapy in 43.4% and in addition to more than two on-going
antidiabetic therapy in 41% of the patients (Table 3a and b).
In the study population (n ¼ 2804), the most commonly re-
ported antidiabetic drug at baselinewasmetformin in 79.3% of
the patients, followed by sulphonylureas in 60.2%, gliptins in
31.1%, alpha glucosidase inhibitors in 18.90%, insulin in 14.7%,
thiazolidinediones in 6.5%, meglitinide analogs in 0.9%, GLP 1
agonist 0.2% and bromocriptine in <1% (Table 3c).
Table 2 e Number of patients (%) with or without on-
going statin therapy at baseline (N ¼ 3133).
With statin 1812 (57.8%)
Atorvastatin 1262 (69.6%)
Rosuvastatin 543 (30.0%)
Pitavastatin 4 (0.2%)
Simvastatin 2 (0.1%)
Pravastatin 1 (0.1%)
Without statin 1321 (42.2%)
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 2 3e2 6 25Saroglitazar in addition to oral antidiabetic medication
showed significant improvement in all lipid and glycemic pa-
rameters at 3 month follow-up. The mean baseline TG was
312.3 mg/dL vs. 188.7 mg/dL at 3 month follow-up, a significant
reductionof 35.8% (meanof%change frombaseline).Non-HDL-
C levels also reported a significant 23.4% mean reduction at 3
month follow-up. A statistically significant improvement in all
other lipid parameters was also noted (a mean reduction of
16.4% in LDL-C levels, 31.5% in VLDL-C levels, 19% in total
cholesterol levels and mean increase of 7.3% in HDL-C levels).
Analysis of glycemic parameters revealed a statistically
significant 0.9% absolute reduction in HbA1c from baseline
value of 8.3% to 7.4% at 3 month follow-up. A significant
reduction in fasting plasma glucose level of 23.6% from amean
baseline of 175.2mg/dL tomean follow-up value of 128.9mg/dL
and a significant 26.3%mean reduction inpost-prandial plasma
glucose level frommean baseline level of 262.4 mg/dL to mean
follow-up value of 185.2 mg/dL were observed (Table 4).
Saroglitazar administration did not lead to weight gain.
Themean bodyweight at baselinewas 72.3 kgs and at 3month
follow-up was 71.6 kgs. No serious adverse events were
reported.4. Discussion
Statins are recommended as the primary therapy for the
management of dyslipidemia in diabetes by variousTable 3 e Pattern of baseline antidiabetic therapy.
a. Number of patients (%) with or without on-going antidiabetic
therapy (N ¼ 3133)
Patients with antidiabetic therapy 2804 (89.5%)
Patients without antidiabetic therapy 329 (10.5%)
b. Number of patients (%) with single, dual or more than two
antidiabetic drugs (n ¼ 2804)
Single antidiabetic drug 433 (15.4%)
Dual antidiabetic drug 1218 (43.4%)
More than two antidiabetic drugs 1153 (41.1%)
c. Pattern of antidiabetic drug; (n ¼ 2804)
Metformin 2486 (79.3%)
Sulphonylureas 1886 (60.2%)
Gliptins 973 (31.1%)
Alpha glucosidase inhibitors 529 (18.90%)
Insulin 460 (14.7%)
Thiazolidinediones 205 (6.5%)
Meglitinide analogs 29 (0.9%)
GLP 1 agonist 6 (0.2%)
Bromocriptine 1 (0.0%)
*Data as number of patients (%).guidelines like the 2013 American Heart Association and the
2015 American Diabetic Association guidelines for the man-
agement of dyslipidemia.8,9 Residual cardiovascular risk re-
mains a major concern after statin therapy and atherogenic
diabetic dyslipidemia is postulated to be a major factor.
Studies have shown that in comparison to Caucasians, In-
dians have higher TG levels and an associated low HDL-C.10,11
High TG has been long debated to be a major risk factor for
CVD and today there is growing evidence which associating
higher TG levels with increased CVD disease. A recent
observational study in more than 75,000 subjects from gen-
eral population, followed up for 34 years has revealed that
lower TG level was associated with lower CV risk. It was
observed that the group with TG <90 mg/dL had 60% lower
risk (statistically significant) of ischemic heart diseases than
those with TG 360 mg/dL.12 Another metaanalysis published
in 2014 revealed that non-fasting TG of 600 mg/dL versus
72 mg/dL was associated with hazard ratio of 5.1 (95% CI
3.5e7.2) for myocardial infarction, 3.2 (2.5e4.1) for ischemic
heart disease, 3.2 (2.2e4.7) for ischemic stroke, and 2.2
(1.8e2.7) for all-cause mortality.13 Thus, higher TG level is
found to be associated with increased cardiovascular risk.
The latest American Association of Clinical Endocrinology
(AACE) dyslipidemia guidelines also recommend a non-HDL-
C calculation rather than LDL-C calculation alone when TG
is above 200 mg/dL but <500 mg/dL for better risk assessment
especially in insulin resistance.14 The AACE diabetes guide-
lines suggest that non-HDL-C goal is to be achieved with TG
lowering therapy after achievement of desirable LDL-C
level.15 The European Society of Cardiology 2011 dyslipide-
mia guidelines recommend TG lowering with drugs to be
considered in subjects with TG more than 2.3 mmol/L (more
than 200 mg/dL) who cannot lower them by lifestyle mea-
sures.16 Metaanalysis of the five major fibrate trials has
shown 35% statistically significant decrease in coronary heart
disease with fibrates in the group with baseline TG 204 mg/
dL and HDL-C 34 mg/dL.17 Thus there is increasing evi-
dences bolstered by guidelines supporting the control of TG to
manage non-HDL-C and cardiovascular risk. Unfortunately,
the currently available options for the treatment of high TG,
fibrates and niacin, are associated with several side effects
which limits their use. The use of fibrates is associated with
higher risk of muscle symptoms when given in conjunction
with statins, increased risk of choleolithiasis, and alteration
in renal and liver parameters.18 Niacin is associated with
decreased patient compliance due to skin flushes, and also
manifests glucose intolerance.19 In this context, saroglitazar,
a novel molecule, is a dual PPAR-a/g agonist, approved for the
use of DD. The present study shows that saroglitazar in
addition to statins led to a significant improvement in lipid
parameters. At 3 month there was a significant reduction in
TG of 35.8%, LDL-C of 16.4%, total cholesterol of 19% and non-
HDL-C of 23.4%. Further, in patients (with average duration of
diabetes of 6.29 years) on existing baseline antidiabetic
medications, the addition of saroglitazar, showed a signifi-
cant 0.9% absolute reduction in HbA1c and significant
improvement in fasting and post prandial plasma glucose.
Finally, there were no serious adverse events or alteration in
liver or renal enzymes and edema or weight gain reported in
this study.
Table 4 e Change in lipid and glycemic parameters after 3 months treatment with saroglitazar 4 mg once daily (N¼ 2804).
Laboratory parameter Baseline 3-month follow up Absolute change Percentage change (%)
TG (mg/dL); n ¼ 2767 312.3 ± 122.65 188.7 ± 61.40 123.7 ± 104.39* 35.8 ± 19.34
LDL-C (mg/dL); n ¼ 2694 139.5 ± 42.16 112.4 ± 30.83 27.1 ± 30.06* 16.4 ± 23.94
HDL-C (mg/dL); n ¼ 2453 38.8 ± 8.65 41.0 ± 7.14 2.1 ± 5.92* 7.3 ± 15.08
VLDL-C (mg/dL); n ¼ 2070 52.0 ± 9.95 34.8 ± 9.07 17.1 ± 10.64* 31.5 ± 18.29
Total cholesterol (mg/dL); n ¼ 2388 240.2 ± 63.04 189.9 ± 41.29 50.3 ± 46.24* 19.0 ± 14.34
Non-HDL-C (mg/dL); n ¼ 2265 201.8 ± 64.08 149.4 ± 41.02 52.3 ± 46.93* 23.4 ± 16.89
HbA1c (%); n ¼ 2612 8.3 ± 1.28 7.4 ± 0.89 0.9 ± 0.85* e
Fasting plasma glucose (mg/dL); n ¼ 2549 175.2 ± 53.34 128.9 ± 33.17 46.3 ± 42.95* 23.6 ± 16.59
Post-prandial plasma glucose (mg/dL); n ¼ 2295 262.4 ± 80.26 185.2 ± 48.25 77.1 ± 65.14* 26.3 ± 17.58
All values in Mean ± SD. Abbreviations: N ¼ number of subjects in specified treatment; n ¼ number of subjects having non-missing values at
baseline and post-baseline visits. p-values are calculated from paired t - test. *p value <0.0001.
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This is not a randomized, controlled clinical trial and this
analysis consist of data obtained from real time clinical
practice. The data were analyzed at a short duration of 3
month follow up. Adherence to therapy could not be assessed
in this analysis. Laboratory tests were not conducted at spe-
cific assigned laboratory. More randomized, controlled clinical
trials with longer duration of follow up will be necessary.6. Conclusions
In patients with diabetic dyslipidemia, the use of saroglitazar
4 mg once daily for 3 month is associated with significant
improvement of lipid and glycemic parameters. Saroglitazar
was safe, well tolerated and there was no serious adverse
event reported.Conflicts of interest
Dr Ashok D Jaiswal is an employee of Cadila Healthcare,
Ahmedabad.
All authors have none to declare.r e f e r e n c e s
1. Global Status Report on Noncommunicable Diseases 2010 [Internet].
World Health Organization; 2015. Available from: http://www.
who.int/nmh/publications/ncd_report_full_en.pdf.
2. Yusuf S, Hawken S, Ounpuu S, On behalf of the INTERHEART
Study Investigators. Effect of potentially modifiable risk
factors associated with myocardial infarction in 52 countries
(the INTERHEART study): case-control study. Lancet.
2004;364:937e952.
3. Mooradian A. Dyslipidemia in type 2 diabetes mellitus. Nat
Clin Pract Endocrinol Metab. 2009;5:150e159.
4. Selby JV, Peng T, Karter AJ, et al. High rates of co-occurrence
of hypertension, elevated low-density lipoprotein cholesterol,
and diabetes mellitus in a large managed care population. Am
J Manag Care. 2004 Feb;10:163e170.
5. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk
and dietary intervention. Lipids. 2010;45:907e914.6. Jani R, Pai V, Jha P, et al. A multicenter, prospective,
randomized, double-blind study to evaluate the safety and
efficacy of saroglitazar 2 and 4 mg Compared with placebo in
type 2 diabetes mellitus patients having hypertriglyceridemia
not controlled with atorvastatin therapy (PRESS VI). Diabetes
Technol Ther. 2014;16:63e71.
7. Pai V, Paneerselvam A, Mukhopadhyay S, et al. A multicenter,
prospective, randomized, double-blind study to evaluate the
safety and efficacy of saroglitazar 2 and 4 mg Compared to
pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J
Diabetes Sci Technol. 2014;8:132e141.
8. Stone N, Robinson J, Lichtenstein A, et al. 2013 ACC/AHA
guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: a report of the
American College of Cardiology/American Heart Association
Task Force on practice guidelines. Circulation.
2013;129:S1eS45.
9. Cardiovascular disease and risk management. Diabetes Care.
2014;38:S49eS57.
10. Joshi S, Anjana R, Deepa M, et al. Prevalence of dyslipidemia
in urban and rural India: the ICMReINDIAB study. PLoS One.
2014;9:e96808.
11. 20th Annual Convention of the American Association of Physicians
of Indian Origin Clinical Implications: Dyslipidemia in the Asian
Indian Population June 29, 2002 [Internet]; 2015. Available from:
https://southasianheartcenter.org/docs/AAPImonograph.pdf.
12. Jørgensen A, Frikke-Schmidt R, Nordestgaard B. Loss-of-
function mutations in APOC3 and risk of ischemic vascular
disease. J Vasc Surg. 2014;60:1096.
13. Nordestgaard B, Varbo A. Triglycerides and cardiovascular
disease. Lancet. 2014;384:626e635.
14. Jellinger PS, Smith DA, Mehta AE, et al. American Association
of Clinical Endocrinologists' Guidelines for Management of
Dyslipidemia and Prevention of Atherosclerosis: executive
summary. Endocr Pract. 2012 MareApr;18:269e293.
15. Garber A, Abrahamson M, Barzilay J, et al. American
association of clinical Endocrinologists' comprehensive
diabetes management algorithm 2013 consensus statement e
executive summary. Endocr Pract. 2013;19:536e557.
16. Catapano A, Chapman J, Wiklund O, Taskinen M. The new
joint EAS/ESC guidelines for the management of
dyslipidaemias. Atherosclerosis. 2011;217:1.
17. Combination lipid therapy in type 2 diabetes. N Engl J Med.
2010;363:692e695.
18. Accessdata.fda.gov. Drug Approval Package: Tricor (Fenofibrate)
NDA #021203 [Internet]; 2015 [cited 14 January 2015]. Available
from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/
2001/21-203_Tricor.cfm.
19. Drugs.com. Niacin Side Effects in Detail [Internet]; 2015 [cited 14
January 2015]. Available from: Drugs.com. http://www.drugs.
com/sfx/niacin-side-effects.html.
